My Portfolio

Incyte Corp INCY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 4:07 PM EDT

97.98UNCH (UNCH)

Volume

96,772

97.98

+5.74 (+6.22%)

Volume

2,170,925

52 week range

64.72 - 112.29

Open93.02
Day High98.48
Day Low92.66
Prev Close92.24
52 Week High112.29
52 Week High Date01/07/26
52 Week Low64.72
52 Week Low Date06/03/25

Latest On Incyte Corp

Stocks making big moves midday: Ferrari, Incyte, S&P Global, Datadog, BP and more February 10, 2026CNBC.com
Here are the 5 big things we're watching in the stock market this weekFebruary 8, 2026CNBC.com
Rate outlook comes under scrutiny next week with jobs, inflation data on deckFebruary 6, 2026CNBC.com
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identityJanuary 13, 2026CNBC.com
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake ShackDecember 9, 2025CNBC.com
These stocks are the most oversold in the selloff and could be due for a bounceNovember 8, 2025CNBC.com
This biotech made it through a 'time correction.' Charts say it could be time to buyOctober 23, 2025CNBC.com
Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higherSeptember 22, 2025CNBC.com
These stocks are overbought with S&P 500 near record highsAugust 16, 2025CNBC.com
These are America's 10 strongest state economies best prepared for a recessionJuly 12, 2025CNBC.com

Key Stats

Market Cap19.575B
Shares Out199.78M
10 Day Average Volume1.38M
Dividend-
Dividend Yield-
Beta0.79

Latest On Incyte Corp

Stocks making big moves midday: Ferrari, Incyte, S&P Global, Datadog, BP and more February 10, 2026CNBC.com
Here are the 5 big things we're watching in the stock market this weekFebruary 8, 2026CNBC.com
Rate outlook comes under scrutiny next week with jobs, inflation data on deckFebruary 6, 2026CNBC.com
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identityJanuary 13, 2026CNBC.com
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake ShackDecember 9, 2025CNBC.com
These stocks are the most oversold in the selloff and could be due for a bounceNovember 8, 2025CNBC.com
This biotech made it through a 'time correction.' Charts say it could be time to buyOctober 23, 2025CNBC.com
Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higherSeptember 22, 2025CNBC.com
These stocks are overbought with S&P 500 near record highsAugust 16, 2025CNBC.com
These are America's 10 strongest state economies best prepared for a recessionJuly 12, 2025CNBC.com

KEY STATS

Open93.02
Day High98.48
Day Low92.66
Prev Close92.24
52 Week High112.29
52 Week High Date01/07/26
52 Week Low64.72
52 Week Low Date06/03/25
Market Cap19.575B
Shares Out199.78M
10 Day Average Volume1.38M
Dividend-
Dividend Yield-
Beta0.79

RATIOS/PROFITABILITY

EPS (TTM)7.07
P/E (TTM)13.85
Fwd P/E (NTM)12.45
EBITDA (TTM)1.545B
ROE (TTM)30.82%
Revenue (TTM)5.361B
Gross Margin (TTM)92.97%
Net Margin (TTM)26.71%
Debt To Equity (MRQ)0.60%

EVENTS

Earnings Date07/27/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Incyte Advances Early-Stage Skin Drug Study, Supporting Long-Term Growth Story5 Hours AgoTipRanks
Bernstein Sticks to Their Hold Rating for Incyte (INCY)June 2, 2026TipRanks
Incyte (INCY) Gets a Buy from Stifel NicolausJune 1, 2026TipRanks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)June 1, 2026TipRanks
Wall Street Analysts Are Bullish on Top Healthcare PicksMay 31, 2026TipRanks

Profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise....

Julian Baker

Independent Chairman of the Board

William Meury

Chief Executive Officer, Director

Pablo Cagnoni

President, Global Head - Research and Development

Thomas Tray

Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer

Suketu Upadhyay

Chief Financial Officer

Matteo Trotta

Executive Vice President, General Manager - Dermatology US

Address

1801 Augustine Cut-Off

Wilmington, DE

19803

United States

https://www.incyte.com/